- Fellowship - University of South Florida/Moffitt Cancer Center (2004-2007), Hematology Oncology
- Residency - Mercy Hospital (2001-2004), Internal Medicine
- Medical School - Damascus University School of Medicine, Syria (1989-1995)
Jade Homsi, M.D.
- Internal Medicine - Hematology/Oncology
- Skin Cancer
Jade Homsi, M.D. is an Associate Professor of Internal Medicine in UT Southwestern Medical Center’s Division of Hematology/Oncology. He is co-leader of the Melanoma Disease Oriented Team at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center, the only NCI-designated cancer center in North Texas. Dr. Homsi specializes in treating patients with melanoma, advanced skin cancer, and soft tissue and bone sarcomas.
Dr. Homsi attended medical school at Damascus University in Syria. He completed a residency in internal medicine at Mercy Hospital in St. Louis and a fellowship in hematology/oncology at the University of South Florida/Moffitt Cancer Center in Tampa. Prior to joining UT Southwestern, Dr. Homsi was an Assistant Professor of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston and its affiliate in Arizona.
Dr. Homsi is dedicated to patient-centered care using evidence-based medicine and novel therapies. He is active in research related to melanoma and sarcoma, with a focus on immunotherapy and early phase clinical trials. He has authored or co-authored more than 40 articles based on his research.
He is board certified in medical oncology, and he is a member of the American Society of Clinical Oncology.
Meet Dr. Homsi
Melanoma and Sarcoma Specialist in Dallas
Prior to joining UT Southwestern in 2017, Dr. Homsi practiced for 10 years at the University of Texas MD Anderson Cancer Center in Houston and the center affiliate in Arizona, which made him very aware that having to travel a long way to get cancer treatment can make a challenging illness even more difficult
“It’s really meaningful for me to be part of a team that offers top-level cancer care right here in Dallas,” he says.
Part of what makes UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center the best in the Metroplex, Dr. Homsi says, is the focused expertise of its cancer physicians.
“Oncologists at UT Southwestern are specialized,” he says. “I don’t treat all kinds of cancer patients – I’ve spent my entire career focused on melanoma and sarcoma. It’s what I do every day.” He says this kind of specialization improves treatment outcomes for patients.
Treating tough cancers
The forms of cancer Dr. Homsi specializes in are known for being sometimes difficult to treat and for being challenging for a general oncologist to treat.
Melanoma is not the most common type of skin cancer, but it is the most serious. Dr. Homsi says it is of particular concern for Texans because of the sunny weather residents enjoy year-round. “Not everyone realizes that melanoma does not stay isolated to the skin,” he says. “it can spread, or metastasize, to the body’s internal organs and becomes life-threatening.”
Recent advances in immunotherapy, the most common treatment for melanoma, have significantly improved the outlook for both survival and quality of life, Dr. Homsi notes.
“People are now living much longer with melanoma than they used to,” he says. “The life expectancy of people with advanced and metastatic melanoma, for example, has more than tripled since the emergence of immunotherapy drugs.”
Dr. Homsi is hoping for and expecting a similar boom in new therapies for sarcoma, a rare form of cancer than can affect any type of connective tissue in the body, from bone and fatty tissue to blood vessels. “Research in sarcoma is definitely progressing,” he says. “We’re investigating several new ways to target sarcoma cancer cells, and we are testing new drugs that could and should improve treatment outcomes for people with sarcoma.”
Part of Dr. Homsi’s work involves participating in clinical research to investigate potential new therapies for melanoma advanced skin cancer and sarcoma. “It’s both interesting and exciting to be a part of that work,” he says. “And participating in research means we can bring the latest advances to our patients quickly.”
Tailored treatment for each patient
Whether he is treating melanoma or sarcoma, Dr. Homsi approaches each patient as an individual and not just another medical case.
“At UT Southwestern we use a team approach to craft our treatment plans,” he says.
“We gather a team of experts from dermatology, surgery, radiation, and other disciplines to come up with the right approach for each patient. Every person is different, and I really enjoy working with patients and helping them make treatment decisions based on their individual needs.
“Our task is not just to treat their cancer. We want to care
for the person, not the cancer.”
- Pain Merit Award 2001, American Society of Clinical Oncology Annual Meeting
- Merit Award 2006, American Society of Clinical Oncology Annual Meeting
- K12 Mentored Clinical Scientist Award 2006-2007, National Institutes of Health
- Team Science Award 2011, Melanoma Research Alliance
Rethinking Phase I Trials: Going beyond toxicity in evaluating new agents in ASCO Education Book
Homsi J (2007)
- Rethinking Phase I Trials: Going beyond toxicity in evaluating new agents in ASCO Education Book
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A Annals of oncology : official journal of the European Society for Medical Oncology 2015 Nov 26 11 2267-74
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Dec 18 24 6758-70
Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG Clinical cancer research : an official journal of the American Association for Cancer Research 2011 Jul 17 14 4882-91
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P Melanoma research 2010 Dec 20 6 507-10
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P Melanoma research 2009 Aug 19 4 238-42
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY Cancer immunology, immunotherapy : CII 2017 Jun
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB Journal of cutaneous pathology 2012 Sep 39 9 821-5
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI Melanoma research 2009 Jun 19 3 167-75
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 13 19 5855-61
Melanoma of the anal canal: a case series.
Homsi J, Garrett C Diseases of the colon and rectum 2007 Jul 50 7 1004-10
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.
- Skin Cancer
- Phase 1 Trials
- Skin Cancer
- Soft Tissue Sarcoma
Q&A by Dr. Homsi
Articles by Dr. Homsi
Showing 1 locations